Boston Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

Boston Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-37,905	Closed	-$737K	–	698
2018 Q1	$737K	Buy	37,905 +10,270	+37%	+$202K	0.02%	428
2017 Q4	$460K	Buy	27,635 +885	+3%	+$16.2K	0.01%	507
2017 Q3	$543K	Buy	+26,750	New	+$511K	0.01%	479
2016 Q3	–	Sell	-11,785	Closed	-$340K	–	705
2016 Q2	$340K	Buy	11,785 +125	+1%	+$4.07K	0.01%	571
2016 Q1	$373K	Hold	11,660	–	–	0.01%	532
2015 Q4	$499K	Buy	+11,660	New	+$466K	0.01%	457

Boston Advisors's IPXL Position: Q2 2018 in Review

Boston Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 37,905 shares — an estimated $737K sold.

Boston Advisors first reported a position in IPXL in Q4 2015 and held it in 6 quarters. The position peaked at $737K in Q1 2018. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

Boston Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
Boston Advisors sold 37,905 Impax Laboratories, Inc. shares in Q2 2018, an estimated $737K.
Boston Advisors first reported a position in Impax Laboratories, Inc. in Q4 2015 and held it in 6 quarters.
Boston Advisors's Impax Laboratories, Inc. position peaked at $737K in Q1 2018.
1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Boston Advisors's 13F filing for Q2 2018, filed 18 Jul 2018.